Evidence map›Paper›PMID 26018166›Full record

ArticleJournal of virology2015

Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2.

Ruchi M Newman, Susanna L Lamers, Brian Weiner, Stuart C Ray, Robert C Colgrove, Fernando Diaz, Lichen Jing, Kening Wang, Sakina Saif, Sarah Young and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Alphaherpesvirus Genomics: Past, Present and Future.Current issues in molecular biology · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Ruchi M NewmanBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA rnewman4@mgh.harvard.edu.
Susanna L LamersBioinfoexperts, LLC, Thibodaux, Louisiana, USA.
Brian WeinerBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Stuart C RayDepartments of Medicine and Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Robert C ColgroveDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts, USA.
Fernando DiazDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Lichen JingDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Kening WangLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sakina SaifBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Sarah YoungBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Matthew HennBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Oliver LaeyendeckerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA.
Aaron A R TobianDepartments of Medicine and Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Jeffrey I CohenLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
David M KoelleDepartment of Medicine, University of Washington, Seattle, Washington, USA Department of Laboratory Medicine and Global Health, University of Washington, Seattle, Washington, USA Vaccine and Infectious Diseases Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Thomas C QuinnDepartments of Medicine and Pathology, Johns Hopkins University, Baltimore, Maryland, USA Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA.
David M KnipeDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Broad Institute · USHarvard University · USJohns Hopkins University · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USFred Hutch Cancer Center · USUniversity of Washington · US

Funding

THE PERINATAL COMPLICATIONS OF ASYMPTOMATIC GENITAL HERPES SIMPLEX VIRUSP01AI030731 · NIAID · UNIVERSITY OF WASHINGTON · PI ZHU, JIA · 1991 to 2017
$34.3M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Herpesvirus Pathogenesis and Vaccine DevelopmentZIAAI000978 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$13.7M
Development Of Vaccines For Genital Herpes Simplex InfectionZIAAI000548 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$12.1M
Pathogenesis and Chemotherapy of Human Virus InfectionsZIAAI000058 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$8.8M
Immunopathogenesis Of Chlamydia trachomatis InfectionZIAAI000358 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2009 to 2022
$7.0M
International Herpes Vaccine ProjectR01AI057552 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KNIPE, DAVID M. · 2005 to 2014
$3.8M
Genomic systems approach to measure HSV-1-specific T-cell dominance in humansR01AI094019 · NIAID · UNIVERSITY OF WASHINGTON · PI KOELLE, DAVID M · 2012 to 2016
$1.9M
International Herpes Vaccine ProjectR56AI057552 · NIAID · HARVARD MEDICAL SCHOOL · PI KNIPE, DAVID M. · 2011 to 2011
$70k
NIAID NIH HHS AI030731NIAID NIH HHS AI057552NIAID NIH HHS HHSN272200900018CNIAID NIH HHS P01 AI030731NIAID NIH HHS R01 AI057552NIAID NIH HHS R01 AI094019NIAID NIH HHS R56 AI057552
6 · The paper itself

Abstract

unlabelledHerpes simplex virus 2 (HSV-2), the principal causative agent of recurrent genital herpes, is a highly prevalent viral infection worldwide. Limited information is available on the amount of genomic DNA variation between HSV-2 strains because only two genomes have been determined, the HG52 laboratory strain and the newly sequenced SD90e low-passage-number clinical isolate strain, each from a different geographical area. In this study, we report the nearly complete genome sequences of 34 HSV-2 low-passage-number and laboratory strains, 14 of which were collected in Uganda, 1 in South Africa, 11 in the United States, and 8 in Japan. Our analyses of these genomes demonstrated remarkable sequence conservation, regardless of geographic origin, with the maximum nucleotide divergence between strains being 0.4% across the genome. In contrast, prior studies indicated that HSV-1 genomes exhibit more sequence diversity, as well as geographical clustering. Additionally, unlike HSV-1, little viral recombination between HSV-2 strains could be substantiated. These results are interpreted in light of HSV-2 evolution, epidemiology, and pathogenesis. Finally, the newly generated sequences more closely resemble the low-passage-number SD90e than HG52, supporting the use of the former as the new reference genome of HSV-2. IMPORTANCE: Herpes simplex virus 2 (HSV-2) is a causative agent of genital and neonatal herpes. Therefore, knowledge of its DNA genome and genetic variability is central to preventing and treating genital herpes. However, only two full-length HSV-2 genomes have been reported. In this study, we sequenced 34 additional HSV-2 low-passage-number and laboratory viral genomes and initiated analysis of the genetic diversity of HSV-2 strains from around the world. The analysis of these genomes will facilitate research aimed at vaccine development, diagnosis, and the evaluation of clinical manifestations and transmission of HSV-2. This information will also contribute to our understanding of HSV evolution.

Indexed as

Genetic VariationGenome, ViralGeographyHerpesvirus 2, HumanHumansRecombination, Genetic

Identifiers

PMID26018166
PMCPMC4524243
OpenAlexW1574060875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.